LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Aktien・Medtronic PLC

Medtronic PLC

Geschlossen

BrancheGesundheitswesen

78.07 6.15

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

73.58

Max

78.18

Schlüsselkennzahlen
By Trading Economics
Einkommen	-231M 1.1B
Verkäufe	57M 9B
KGV Branchendurchschnitt	20.665 49.888
EPS	1.36
Dividendenrendite	3.83
Gewinnspanne	12.675
Angestellte	95,000
EBITDA	124M 2.5B

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+40.62% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	3.83% 2.38%
Nächste Dividendenausschüttung	17. Juli 2026
Nächstes Ex-Dividendendatum	26. Juni 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-33B 95B
Vorheriger Eröffnungskurs	71.92
Vorheriger Schlusskurs	78.07

Nachrichtenstimmung

By Acuity

38%

62%

109 / 344 Ranking in Healthcare

Medtronic PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Medtronic PLC Prognose

Kursziel

By TipRanks

40.62% Vorteil

12-Monats-Prognose

Durchschnitt 103.71 USD 40.62%

Hoch 120 USD

Tief 84 USD

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Medtronic PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

18 ratings

Buy

Halten

Sell

Basierend auf 18 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Medtronic PLC – Dist abgegeben haben.

Stimmung

By Acuity

109 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.